or Try an Advanced Search...

    Duligotuzumab Stocks List

    Symbol Grade Name % Change
    ELEV B Elevation Oncology, Inc. 6.67
    SLRN F Acelyrin Inc. -4.56
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Clinical Medicine Advanced Solid Tumors Biopharmaceutical Biotechnology Cancer Chronic Urticaria Drugs Health Sciences Hidradenitis Suppurativa Immunology Life Sciences Monoclonal Antibodies Monoclonal Antibody Pharmacy Psoriatic Arthritis Thyroid Eye Disease Treatment Of Cancer Uveitis

    Related ETFs - A few ETFs which own one or more of the above listed Duligotuzumab stocks.

    Symbol Grade Name Weight
    IWC C iShares Microcap ETF 0.04
    IBB D iShares Nasdaq Biotechnology Index Fund 0.03
    IWN C iShares Russell 2000 Value ETF 0.02
    AVSC C Avantis U.S. Small Cap Equity ETF 0.02
    IWM C iShares Russell 2000 ETF 0.01
    View all Duligotuzumab ETFs...
    Compare ETFs
    Compare IBB to AVSC Compare IWC to AVSC Compare IWN to IWM

        Duligotuzumab Stocks Recent News

        Date Stock Title
        Apr 22 ELEV Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
        Related Industries: Biotechnology
        Related Stock Lists: Clinical Medicine Advanced Solid Tumors Biopharmaceutical Biotechnology Cancer Chronic Urticaria Drugs Health Sciences Hidradenitis Suppurativa Immunology Life Sciences Monoclonal Antibodies Monoclonal Antibody Pharmacy Psoriatic Arthritis Thyroid Eye Disease Treatment Of Cancer Uveitis
        Duligotuzumab

        Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3. It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.

        More about Duligotuzumab
        Browse All Tags